Ohr Pharmaceutical Inc (OHRP) 8.55 $OHRP
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mp6p4/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Alcon Nordic - Allergan - AlphaMab - Amakem - BIOCAD - Boehringer Ingelheim - Charlesson - Circadian Technologies - EyeCyte - EyeGate Pharmaceuticals - F. Hoffmann-La Roche - Genzyme - Icon Bioscience - Iconic Therapeutics - Intas Pharmaceuticals - Kala Pharmaceuticals - Lpath - Mesoblast - Neurotech Pharmaceuticals - Novartis - Ohr Pharmaceutical - Omeros Corporation - Ophthotech - Oxford BioMedica - PanOptica - Pfenex - Pfizer - Quark Pharmaceuticals - Regeneron Pharmaceuticals - Santen Pharmaceutical - Sanwa Kagaku Kenkyusho - Senju Pharmaceutical - TRACON Pharmaceuticals - Tacere Therapeutics - ThromboGenics - iCo Therapeutics - pSivida For more information visit http://www.researchandmarkets.com/research/9m...eovascular
AGN: 208.47 (-2.67), EYEG: (), OHRP: 8.55 (unch), REGN: 416.44 (-7.91), OMER: 22.81 (+0.12), NVS: 93.52 (-0.82)
Cancer Cachexia - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/nngtcd/cancer_cachexia) has announced the addition of the "Cancer Cachexia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Cachexia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - Eli Lilly and Company - Novartis - Aphios - GTx - Incyte - AEterna Zentaris - Helsinn Healthcare - Radius Health - Vicus Therapeutics - Ohr Pharmaceutical - KAEL-GemVax - RaQualia Pharma - Acacia Pharma - PsiOxus Therapeutics - Signablok - Myomics For more information visit http://www.researchandmarkets.com/research/nn...r_cachexia
RDUS: 26.38 (+1.78), AMGN: 164.53 (-1.55), AEZS: 0.60 (+0.03), OHRP: 8.55 (unch), LLY: 69.55 (-2.06), NVS: 93.52 (-0.82)
Ohr Pharmaceutical to Present at the Oppenheimer & Co., Inc. 25th Annual Healthcare Conference
GlobeNewswire - Tue Dec 02, 7:00AM CST
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Irach Taraporewala, Chief Executive Officer, will present a corporate overview and business update at the Oppenheimer & Co., Inc.'s 25 Annual Healthcare Conference, being held at the Crowne Plaza Hotel in New York City on December 10-11, 2014.
OHRP: 8.55 (unch)
Profire Energy - A Classic Pump And Dump, Sell Before You Get Burned, Stock Worth $1.00
Small Cap Machine - at Seeking Alpha - Sat Nov 22, 4:00AM CST
PFIE: 2.40 (-0.02), OHRP: 8.55 (unch)
Ohr Pharmaceutical to Host Key Opinion Leader Meeting and Webcast on October 31 in New York City
GlobeNewswire - Mon Oct 27, 7:01AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will host a Key Opinion Leader analyst breakfast on Friday, October 31, 2014 from 8:00 am-9:30 am Eastern Time in New York City. The meeting will feature discussions by two retinal disease experts, K. Bailey Freund, M.D., and Ohr's Chief Medical Officer, Jason S. Slakter, MD.
OHRP: 8.55 (unch)
Ohr Pharmaceutical Announces New Positive Anatomic and Visual Acuity Data on OHR-102 (Squalamine Eye Drops) IMPACT Study Presented at the 2014 American Academy of Ophthalmology Scientific Meeting
GlobeNewswire - Mon Oct 20, 6:15AM CDT
Reduction of Subretinal Hyperreflective Material (SHRM) Induced by OHR-102 Correlates With Improved Vision Outcomes
OHRP: 8.55 (unch)
Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents
at The Street - Fri Oct 17, 6:05AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
AVNR: 16.95 (-0.02), OHRP: 8.55 (unch), MNKD: 5.11 (-0.14), ARNA: 3.91 (-0.18)
Ohr Pharmaceutical's OHR-102 to Enter Phase III in 1H15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 6:00PM CDT
Ohr Pharmaceutical, Inc.'s (OHRP) OHR-102 will enter phase III studies with the primary endpoint being improvement in visual acuity at 9 months.
AMPE: 3.66 (+0.15), OHRP: 8.55 (unch), REGN: 416.44 (-7.91)
Ohr Pharmaceutical Announces Successful End of Phase II Meeting With the FDA on Squalamine Eye Drops (OHR-102) in Wet AMD
GlobeNewswire - Tue Oct 14, 6:15AM CDT
Primary Endpoint for Approval to be Based on Visual Acuity Improvements at 9 Months
OHRP: 8.55 (unch)
Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the 2014 American Academy of Ophthalmology Scientific Meeting
GlobeNewswire - Tue Oct 07, 7:02AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that additional positive anatomic and visual acuity data from the IMPACT study, a phase II clinical trial evaluating Squalamine eye drops (OHR-102) for the treatment of the wet form of age-related macular degeneration (wet AMD), will be presented in two separate podium sessions at the 2014 American Academy of Ophthalmology (AAO) Annual Scientific Meeting, being held in Chicago, Illinois, from October 17-21, 2014.
OHRP: 8.55 (unch)
Retinal Vein Occlusion - Pipeline Review, H2 2014 - 8 Companies & 10 Drug Profiles
M2 - Fri Sep 12, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3bmznr/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Allergan, Inc. - pSivida Corp. - NicOx S.A. - ThromboGenics NV - Ohr Pharmaceutical Inc. - Kala Pharmaceuticals, Inc. - Mabion SA Drug Profiles - fluocinolone acetonide - squalamine lactate - beclomethasone dipropionate - loteprednol etabonate - ranibizumab - ocriplasmin (recombinant) - NCX-434 - NCX-422 - AVA-101 - ranibizumab biosimilar For more information visit http://www.researchandmarkets.com/research/3b...tinal_vein
AGN: 208.47 (-2.67), OHRP: 8.55 (unch)
Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the Retina Society 47th Annual Scientific Meeting
GlobeNewswire - Tue Sep 09, 8:04AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that data from the IMPACT study, a phase II clinical trial evaluating Squalamine eye drops (OHR-102) for the treatment of the wet form of age-related macular degeneration (wet AMD), will be presented in two separate sessions at the Retina Society 47 Annual Scientific Meeting, being held in Philadelphia, Pennsylvania from September 11-14, 2014.
OHRP: 8.55 (unch)
Ohr Pharmaceutical Announces Additional Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Wet-AMD; The IMPACT Study
GlobeNewswire - Wed Aug 13, 7:30AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced additional interim data from the Phase II study evaluating Squalamine Eye Drops (OHR-102) for the treatment of the wet form of age-related macular degeneration ("wet-AMD"
. The data demonstrated a visual acuity and anatomical benefit for the group of patients receiving the combination of OHR-102 and Lucentis PRN ("OHR-102 arm" versus placebo eye drops plus Lucentis PRN ("Lucentis monotherapy arm" . Jason Slakter, MD, retina specialist and Chief Medical Officer at Ohr, presented the data on Tuesday, August 12 at the 2014 Annual Meeting of the American Society of Retina Specialists ("ASRS" .
OHRP: 8.55 (unch)
Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion
GlobeNewswire - Mon Aug 11, 8:59AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced data supporting the use of Squalamine Eye Drops (OHR-102) in the treatment of macular edema secondary to branch (BRVO) or central retinal vein occlusion (CRVO). The data demonstrated that the combination of topical Squalamine eye drops and intravitreal Lucentis(R) led to a mean gain in visual acuity ("VA" of 20.3 letters and resolution of the fovial edema in 95% of the patients at week 10. John Wroblewski, MD, retina specialist at Cumberland Valley Retina Consultants, presented the 10 week data on Saturday, August 9 at the 2014 Annual Meeting of the American Society of Retina Specialists.
OHRP: 8.55 (unch)
Ohr Pharmaceutical to Present at the 2014 Wedbush Life Sciences Management Access Conference
GlobeNewswire - Fri Aug 08, 7:04AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Sam Backenroth, Chief Financial Officer, will present a corporate overview and business update at the 2014 Wedbush Life Sciences Management Access Conference, being held at the Le Parker Meridien Hotel in New York City on August 12-13, 2014.
OHRP: 8.55 (unch)
Ohr Pharmaceutical Announces Upcoming Squalamine Eye Drop Clinical Data Presentations at the 2014 Annual Meeting of the American Society of Retina Specialists
GlobeNewswire - Thu Aug 07, 8:32AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that data from clinical studies evaluating Squalamine eye drops for the treatment of macular edema secondary to central and branch retinal vein occlusion, and the wet form of age-related macular degeneration (wet AMD), will be presented in two separate sessions at the 2014 Annual Meeting of the American Society of Retina Specialists, being held at the Hilton Bayfront Hotel in San Diego, California.
OHRP: 8.55 (unch)
Can the Rally in OHR Pharmaceutical (OHRP) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 8:19AM CDT
Can the Rally in OHR Pharmaceutical (OHRP) Shares Continue?
OHRP: 8.55 (unch)
4 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Aug 01, 6:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
CRMD: 1.39 (-0.04), ACRX: 6.40 (unch), THLD: 3.05 (-0.03), OHRP: 8.55 (unch)
Anacor Pharmaceuticals, Inc. (ANAC) in Focus: Stock Surges 6.76% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 7:44AM CDT
Anacor Pharmaceuticals, Inc. (ANAC) was a big mover last session, as the company saw its shares surge nearly 7% on the day.
SGYP: 2.93 (-0.05), BCRX: 10.06 (+0.02), OHRP: 8.55 (unch), ANAC: 33.86 (-0.82)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mp6p4/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Alcon Nordic - Allergan - AlphaMab - Amakem - BIOCAD - Boehringer Ingelheim - Charlesson - Circadian Technologies - EyeCyte - EyeGate Pharmaceuticals - F. Hoffmann-La Roche - Genzyme - Icon Bioscience - Iconic Therapeutics - Intas Pharmaceuticals - Kala Pharmaceuticals - Lpath - Mesoblast - Neurotech Pharmaceuticals - Novartis - Ohr Pharmaceutical - Omeros Corporation - Ophthotech - Oxford BioMedica - PanOptica - Pfenex - Pfizer - Quark Pharmaceuticals - Regeneron Pharmaceuticals - Santen Pharmaceutical - Sanwa Kagaku Kenkyusho - Senju Pharmaceutical - TRACON Pharmaceuticals - Tacere Therapeutics - ThromboGenics - iCo Therapeutics - pSivida For more information visit http://www.researchandmarkets.com/research/9m...eovascular
AGN: 208.47 (-2.67), EYEG: (), OHRP: 8.55 (unch), REGN: 416.44 (-7.91), OMER: 22.81 (+0.12), NVS: 93.52 (-0.82)
Cancer Cachexia - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/nngtcd/cancer_cachexia) has announced the addition of the "Cancer Cachexia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Cachexia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - Eli Lilly and Company - Novartis - Aphios - GTx - Incyte - AEterna Zentaris - Helsinn Healthcare - Radius Health - Vicus Therapeutics - Ohr Pharmaceutical - KAEL-GemVax - RaQualia Pharma - Acacia Pharma - PsiOxus Therapeutics - Signablok - Myomics For more information visit http://www.researchandmarkets.com/research/nn...r_cachexia
RDUS: 26.38 (+1.78), AMGN: 164.53 (-1.55), AEZS: 0.60 (+0.03), OHRP: 8.55 (unch), LLY: 69.55 (-2.06), NVS: 93.52 (-0.82)
Ohr Pharmaceutical to Present at the Oppenheimer & Co., Inc. 25th Annual Healthcare Conference
GlobeNewswire - Tue Dec 02, 7:00AM CST
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Irach Taraporewala, Chief Executive Officer, will present a corporate overview and business update at the Oppenheimer & Co., Inc.'s 25 Annual Healthcare Conference, being held at the Crowne Plaza Hotel in New York City on December 10-11, 2014.
OHRP: 8.55 (unch)
Profire Energy - A Classic Pump And Dump, Sell Before You Get Burned, Stock Worth $1.00
Small Cap Machine - at Seeking Alpha - Sat Nov 22, 4:00AM CST
PFIE: 2.40 (-0.02), OHRP: 8.55 (unch)
Ohr Pharmaceutical to Host Key Opinion Leader Meeting and Webcast on October 31 in New York City
GlobeNewswire - Mon Oct 27, 7:01AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will host a Key Opinion Leader analyst breakfast on Friday, October 31, 2014 from 8:00 am-9:30 am Eastern Time in New York City. The meeting will feature discussions by two retinal disease experts, K. Bailey Freund, M.D., and Ohr's Chief Medical Officer, Jason S. Slakter, MD.
OHRP: 8.55 (unch)
Ohr Pharmaceutical Announces New Positive Anatomic and Visual Acuity Data on OHR-102 (Squalamine Eye Drops) IMPACT Study Presented at the 2014 American Academy of Ophthalmology Scientific Meeting
GlobeNewswire - Mon Oct 20, 6:15AM CDT
Reduction of Subretinal Hyperreflective Material (SHRM) Induced by OHR-102 Correlates With Improved Vision Outcomes
OHRP: 8.55 (unch)
Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents
at The Street - Fri Oct 17, 6:05AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
AVNR: 16.95 (-0.02), OHRP: 8.55 (unch), MNKD: 5.11 (-0.14), ARNA: 3.91 (-0.18)
Ohr Pharmaceutical's OHR-102 to Enter Phase III in 1H15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 6:00PM CDT
Ohr Pharmaceutical, Inc.'s (OHRP) OHR-102 will enter phase III studies with the primary endpoint being improvement in visual acuity at 9 months.
AMPE: 3.66 (+0.15), OHRP: 8.55 (unch), REGN: 416.44 (-7.91)
Ohr Pharmaceutical Announces Successful End of Phase II Meeting With the FDA on Squalamine Eye Drops (OHR-102) in Wet AMD
GlobeNewswire - Tue Oct 14, 6:15AM CDT
Primary Endpoint for Approval to be Based on Visual Acuity Improvements at 9 Months
OHRP: 8.55 (unch)
Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the 2014 American Academy of Ophthalmology Scientific Meeting
GlobeNewswire - Tue Oct 07, 7:02AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that additional positive anatomic and visual acuity data from the IMPACT study, a phase II clinical trial evaluating Squalamine eye drops (OHR-102) for the treatment of the wet form of age-related macular degeneration (wet AMD), will be presented in two separate podium sessions at the 2014 American Academy of Ophthalmology (AAO) Annual Scientific Meeting, being held in Chicago, Illinois, from October 17-21, 2014.
OHRP: 8.55 (unch)
Retinal Vein Occlusion - Pipeline Review, H2 2014 - 8 Companies & 10 Drug Profiles
M2 - Fri Sep 12, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3bmznr/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Allergan, Inc. - pSivida Corp. - NicOx S.A. - ThromboGenics NV - Ohr Pharmaceutical Inc. - Kala Pharmaceuticals, Inc. - Mabion SA Drug Profiles - fluocinolone acetonide - squalamine lactate - beclomethasone dipropionate - loteprednol etabonate - ranibizumab - ocriplasmin (recombinant) - NCX-434 - NCX-422 - AVA-101 - ranibizumab biosimilar For more information visit http://www.researchandmarkets.com/research/3b...tinal_vein
AGN: 208.47 (-2.67), OHRP: 8.55 (unch)
Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the Retina Society 47th Annual Scientific Meeting
GlobeNewswire - Tue Sep 09, 8:04AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that data from the IMPACT study, a phase II clinical trial evaluating Squalamine eye drops (OHR-102) for the treatment of the wet form of age-related macular degeneration (wet AMD), will be presented in two separate sessions at the Retina Society 47 Annual Scientific Meeting, being held in Philadelphia, Pennsylvania from September 11-14, 2014.
OHRP: 8.55 (unch)
Ohr Pharmaceutical Announces Additional Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Wet-AMD; The IMPACT Study
GlobeNewswire - Wed Aug 13, 7:30AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced additional interim data from the Phase II study evaluating Squalamine Eye Drops (OHR-102) for the treatment of the wet form of age-related macular degeneration ("wet-AMD"
. The data demonstrated a visual acuity and anatomical benefit for the group of patients receiving the combination of OHR-102 and Lucentis PRN ("OHR-102 arm" versus placebo eye drops plus Lucentis PRN ("Lucentis monotherapy arm" . Jason Slakter, MD, retina specialist and Chief Medical Officer at Ohr, presented the data on Tuesday, August 12 at the 2014 Annual Meeting of the American Society of Retina Specialists ("ASRS" . OHRP: 8.55 (unch)
Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion
GlobeNewswire - Mon Aug 11, 8:59AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced data supporting the use of Squalamine Eye Drops (OHR-102) in the treatment of macular edema secondary to branch (BRVO) or central retinal vein occlusion (CRVO). The data demonstrated that the combination of topical Squalamine eye drops and intravitreal Lucentis(R) led to a mean gain in visual acuity ("VA"
of 20.3 letters and resolution of the fovial edema in 95% of the patients at week 10. John Wroblewski, MD, retina specialist at Cumberland Valley Retina Consultants, presented the 10 week data on Saturday, August 9 at the 2014 Annual Meeting of the American Society of Retina Specialists. OHRP: 8.55 (unch)
Ohr Pharmaceutical to Present at the 2014 Wedbush Life Sciences Management Access Conference
GlobeNewswire - Fri Aug 08, 7:04AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Sam Backenroth, Chief Financial Officer, will present a corporate overview and business update at the 2014 Wedbush Life Sciences Management Access Conference, being held at the Le Parker Meridien Hotel in New York City on August 12-13, 2014.
OHRP: 8.55 (unch)
Ohr Pharmaceutical Announces Upcoming Squalamine Eye Drop Clinical Data Presentations at the 2014 Annual Meeting of the American Society of Retina Specialists
GlobeNewswire - Thu Aug 07, 8:32AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that data from clinical studies evaluating Squalamine eye drops for the treatment of macular edema secondary to central and branch retinal vein occlusion, and the wet form of age-related macular degeneration (wet AMD), will be presented in two separate sessions at the 2014 Annual Meeting of the American Society of Retina Specialists, being held at the Hilton Bayfront Hotel in San Diego, California.
OHRP: 8.55 (unch)
Can the Rally in OHR Pharmaceutical (OHRP) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 8:19AM CDT
Can the Rally in OHR Pharmaceutical (OHRP) Shares Continue?
OHRP: 8.55 (unch)
4 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Aug 01, 6:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
CRMD: 1.39 (-0.04), ACRX: 6.40 (unch), THLD: 3.05 (-0.03), OHRP: 8.55 (unch)
Anacor Pharmaceuticals, Inc. (ANAC) in Focus: Stock Surges 6.76% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 7:44AM CDT
Anacor Pharmaceuticals, Inc. (ANAC) was a big mover last session, as the company saw its shares surge nearly 7% on the day.
SGYP: 2.93 (-0.05), BCRX: 10.06 (+0.02), OHRP: 8.55 (unch), ANAC: 33.86 (-0.82)
